R&D Trends

Sarepta, Genethon collaborate for Duchenne muscular dystrophy

Wednesday, June 21, 2017

Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, and Genethon, a non-profit R&D organization dedicated to the development of biotherapies for orphan genetic diseases from research to clinical validation, have signed a gene therapy research collaboration to jointly develop treatments for Duchenne muscular dystrophy (DMD). Genethon’s micro-dystrophin gene therapy approach can target the majority of patients with DMD. Genethon has demonstrated proof-of-concept of their micro-dystrophin program via robust gene expression in a large animal model of DMD.

[Read More]

LEO Science & Tech Hub, Brigham and Women’s Hospital collaborate

Thursday, June 15, 2017

LEO Science & Tech Hub announced a two-year collaboration with the Karp Lab at Brigham and Women’s Hospital (BWH) to develop minimally-invasive technology to advance dermal biomarker assessment. The Karp Lab, led by Jeffrey Karp, Ph.D., at BWH focuses on the development of platform technology and translational research to improve patient care. LEO Science & Tech Hub is an R&D innovation unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases.

[Read More]

LifeArc, previously MRC Technology, to invest £500M

Thursday, June 15, 2017

LifeArc, the U.K. medical research charity previously known as MRC Technology, announced plans to improve the lives of patients suffering from diseases that present the greatest challenges to medical research. By investing up to £500 million over the next five years, LifeArc will seek to generate, fund and champion innovations in antimicrobials, neuroscience, personalized oncology and respiratory medicine.

[Read More]

Evotec joins NURTuRE Consortium

Wednesday, June 14, 2017

Evotec has joined the NURTuRE consortium to drive kidney disease focused drug discovery based on patient derived-data. NURTuRE is uniquely positioned to collect clinical data at the U.K. Renal Registry and analyze samples of 14 kidney disease centers in the U.K., constituting one of the largest kidney patient registries worldwide.

[Read More]